IGF-1R antibody and its use as addressing vehicle for the treatment of cancer
US11365259B2 · kind B2 · utility
1Cited by
12References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2018 |
| Grant date | Jun 21, 2022 |
| Priority date | — |
| Expiry date | Aug 12, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.